United Kingdom based
At the forefront of small molecule drug discovery
We are the first company to automate drug design, surpassing conventional human endeavour.
Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.
With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.
With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.
Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
bispecific drugs polypharmacology drug design
TechnologiesAI Companies (Drug Discovery) Pharmaceutical and Drug Discovery
Posts Mentioning This Company
ML for predicting ADME, novelty, synthetic accessibility, pharmacology of molecules. Single and multi-target prediction. Developed a (lead candidate) bispecific, dual-agonist compound that selectively activates two GPCR families -- for Sumitomo pharma (end of 2015)
Oncology, Inflammation & Immunity
No services posted yet